Tuesday, 3 December 2013

Largest Global Survey Investigating Early Type 2 Diabetes Conversations 

Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation. More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey (Boehringer Ingelheim)

Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome

These biomarkers will help to improve research and management of diabetes. In particular, several biomarkers identified could be used for early identification of diabetes risk (The Lancet Diabetes & Endocrinology)

No comments:

Post a Comment